Lantheus Holdings

The latest read

Computed from the data on Oct 23, 2026. Every figure links back to its source in the sections below.

• Revenue over the four quarters to June 30, 2026: $1.56 billion, up 2.6% from a year earlier.SEC EDGAR filings (XBRL)
• Free cash flow (operating cash flow minus capital expenditure) over the four quarters to December 31, 2023: $0.26 billion, up 1200% from a year earlier.SEC EDGAR filings (XBRL)
• Capital expenditure over the four quarters to December 31, 2023: $0.05 billion, down 81% from a year earlier.SEC EDGAR filings (XBRL)
• Share buybacks in the fiscal year to December 31, 2025: $0.30 billion.SEC EDGAR filings (10-K)
• Latest earnings call or results release (August 6, 2026): sentiment -0.20 on a −1 to +1 scale (negative), confidence 0.00 of 1.Palanor Discourse
• Latest annual report (filed February 26, 2026): 5 risk factors added, 1 removed.Risk Factor Changes (10-K Item 1A)
• Insiders were net sellers in Q3 2025: $383 million on the open market.SEC Form 4
• 466 institutional managers reported a position at June 30, 2026 (+59 on the quarter before).SEC Form 13F
• H-1B filings certified in Q2 2026: 1 (4 a year earlier).U.S. Department of Labor (OFLC)

Company Posture covers S&P 500 companies.

No bond term sheets or tagged debt on file for Lantheus Holdings yet.

Charts

Live charts: each one redraws from today’s data and has an image link to paste into a document or slide.

In the news

Headlines that name Lantheus Holdings, with the publisher and a link. The tone is read from each headline’s own words, never from a summary of the article.

30 days

1 headlines

0% positive · 0% negative

90 days

1 headlines

0% positive · 0% negative

• Neutral
  CMS Grants Transitional Pass-Through Payment Status to Lantheus (LNTH) PYLARIFY TruVu Injection

  gurufocus.com · via Marketaux · Sep 30, 2026

Filings and records

The last two years of notable 8-Ks, offerings, annual reports, federal awards, lobbying reports, patents and other public records, newest first.

1. Oct 20, 2026Lobbying
   Lobbying report (TARPLIN, DOWNS & YOUNG, LLC)third_quarter 2026 · $0.1 million
2. Oct 20, 2026Lobbying
   Lobbying report (FARRAGUT PARTNERS LLP)third_quarter 2026 · $0.1 million
3. Oct 19, 2026Lobbying
   Lobbying report (LANTHEUS HOLDINGS, INC.)third_quarter 2026 · $0.3 million
4. Oct 14, 20268-K
   Shareholder vote resultsItem 5.07
5. Sep 15, 2026Patent
   Patent granted: SYSTEMS AND METHODS FOR AI-ASSISTED ANALYSIS OF PRIMARY TUMOR IMAGES FOR PREDICTION OF METASTASESUS 12737884
6. Aug 4, 20268-K
   Material agreement signedItem 1.01
7. Aug 4, 20268-K
   Director or officer changeItem 5.02
8. Jul 20, 2026Lobbying
   Lobbying report (LANTHEUS HOLDINGS, INC.)second_quarter 2026 · $0.3 million
9. Jul 20, 2026Lobbying
   Lobbying report (TARPLIN, DOWNS & YOUNG, LLC)second_quarter 2026 · $0.1 million
10. Jul 20, 2026Lobbying
    Lobbying report (FARRAGUT PARTNERS LLP)second_quarter 2026 · $0.1 million
11. May 19, 2026Patent
    Patent granted: IMMUNOTHERANOSTIC AGENT TARGETING MESENCHYMAL STEM CELL-DERIVED CANCER CELLS AND MESENCHYMAL STEM CELL ASSOCIATED DISEASEUS 12629432
12. May 1, 20268-K
    Director or officer changeItem 5.02
13. May 1, 20268-K
    Shareholder vote resultsItem 5.07
14. Apr 20, 2026Lobbying
    Lobbying report (LANTHEUS HOLDINGS, INC.)first_quarter 2026 · $0.3 million
15. Apr 20, 2026Lobbying
    Lobbying report (TARPLIN, DOWNS & YOUNG, LLC)first_quarter 2026 · $0.1 million
16. Apr 14, 2026Patent
    Patent granted: SYSTEMS AND METHODS FOR RAPID NEURAL NETWORK-BASED IMAGE SEGMENTATION AND RADIOPHARMACEUTICAL UPTAKE DETERMINATIONUS 12602772
17. Apr 7, 2026Patent
    Patent granted: SYSTEMS AND METHODS FOR AUTOMATED IDENTIFICATION AND CLASSIFICATION OF LESIONS IN LOCAL LYMPH AND DISTANT METASTASESUS 12597127
18. Mar 10, 2026Patent
    Patent granted: SYSTEMS AND METHODS FOR PLATFORM AGNOSTIC WHOLE BODY IMAGE SEGMENTATIONUS 12573050
19. Feb 26, 202610-K
    Annual report (10-K)5 risk factors added, 1 removed
20. Nov 12, 20258-K
    Director or officer changeItem 5.02
21. Nov 6, 20258-K
    Director or officer changeItem 5.02
22. Aug 11, 20258-K
    Director or officer changeItem 5.02
23. Jul 22, 20258-K
    Acquisition or sale completedItem 2.01
24. May 5, 20258-K
    Shareholder vote resultsItem 5.07
25. Apr 1, 20258-K
    Acquisition or sale completedItem 2.01
26. Feb 26, 202510-K
    Annual report (10-K)3 risk factors added, 4 removed
27. Jan 30, 20258-K
    Director or officer changeItem 5.02
28. Jan 28, 20258-K
    Material agreement signedItem 1.01
29. Jan 13, 20258-K
    Material agreement signedItem 1.01
30. Dec 23, 20248-K
    Material agreement signedItem 1.01
31. Feb 22, 202410-K
    Annual report (10-K)1 risk factors added, 5 removed

Peers

Companies in the same sector in the S&P 500, Russell 1000 or MidCap 400, closest in revenue first. Trailing twelve months, from SEC filings.

Identity

SEC CIK

1521036

LEI

5299005HUB5IOJGO7S39